What's the difference between screening and confirmation in drug testing?
Drug testing uses two analytical steps that answer different questions. Screening by Immunoassay is fast and sensitive — it asks "could this sample contain the drug we're looking for?" Confirmation by GC-MS (gas chromatography–mass spectrometry) or LC-MS/MS (liquid chromatography–tandem mass spectrometry) is precise and specific — it asks "is this specific molecule, in fact, present above the laboratory's cutoff?" Both steps are essential to a defensible result.
Why two-step testing exists
A single-method drug test would have to be both sensitive (catch all true positives) and specific (reject all false positives). No single analytical method does both well. Immunoassays are sensitive but susceptible to cross-reactivity (false positives). Mass spectrometry is specific but expensive and time-consuming. The two-step structure uses immunoassay to screen out the obvious negatives quickly, then uses mass spectrometry to investigate the non-negatives with forensic precision.
This is also why a non-negative screening result is not a positive: it is a flag that triggers the confirmation step.
Immunoassay — the screening step
Immunoassays use antibodies that bind to a target drug or metabolite. When the sample's analyte binds to the antibody, it displaces a labeled reference molecule, producing a measurable signal — color change, fluorescence, or enzymatic activity. There are several immunoassay technologies in common use:
- EMIT (Enzyme Multiplied Immunoassay Technique) — historically dominant in clinical and workplace settings.
- CEDIA (Cloned Enzyme Donor Immunoassay).
- KIMS (Kinetic Interaction of Microparticles in Solution).
- FPIA (Fluorescence Polarization Immunoassay).
- Lateral-flow immunoassay — the strip used in at-home and instant-result tests.
All share the same limitation: cross-reactivity. Structurally similar molecules can bind the same antibody, producing false positives at the screening cutoff. See understanding false positives for the common cross-reactants by drug class.
Mass spectrometry — the confirmation step
Mass spectrometry confirms or rejects screening positives by separating molecules by mass-to-charge ratio. There are two principal confirmation technologies in workplace drug testing:
- GC-MS (gas chromatography–mass spectrometry) — the historical workhorse for confirmation testing of THC-COOH, cocaine metabolites, opiates, amphetamines, and PCP.
- LC-MS/MS (liquid chromatography–tandem mass spectrometry) — increasingly used for lower-cutoff analytes (fentanyl, benzodiazepines) and for panels where GC-MS sample preparation is impractical.
Either method achieves the specificity required by federal Mandatory Guidelines: a confirmation result is reported only when the analyte's mass-spectrometric "fingerprint" matches the reference within tight tolerances and the quantitative concentration is above the confirmation cutoff.
Screening vs confirmation cutoffs
Cutoff levels differ between the two steps. The screening cutoff is set higher because immunoassay is less specific; the confirmation cutoff is set lower because mass spectrometry can identify and quantify with precision. For example, the federal cannabinoid cutoffs are:
- Screening: 50 ng/mL THC-COOH
- Confirmation: 15 ng/mL THC-COOH
A sample that screens above 50 ng/mL goes to confirmation. The confirmation reports a quantitative result; if that result is at or above 15 ng/mL, the laboratory reports a positive to the MRO. Below 15 ng/mL on confirmation, the result is reported negative.
The MRO review step
Even a confirmed laboratory positive is not yet a "verified positive" for workplace purposes. The Medical Review Officer reviews the result with the donor to identify any legitimate medical explanation — a prescription, an OTC medication, a dietary factor — and reports a verified result to the employer. See MRO & confirmation for the process detail.
Lab QA and proficiency
SAMHSA-certified laboratories must maintain documented quality assurance and pass proficiency testing on regular schedules. The certification requires:
- Documented standard operating procedures.
- Blind quality-control samples integrated into routine workflow.
- Independent proficiency testing (PT) administered by the National Laboratory Certification Program.
- Documented chain of custody on every specimen.
- Defined roles for the responsible person, certifying scientist, and certifying technicians.
Sources & references
drugtest.co content is sourced from primary regulatory and clinical references. We do not cite gray-market or "how to pass" sources.